» Articles » PMID: 21542849

Pre-emptive Morphine Treatment Abolishes Nerve Injury-induced Lysophospholipid Synthesis in Mass Spectrometrical Analysis

Overview
Journal J Neurochem
Specialties Chemistry
Neurology
Date 2011 May 6
PMID 21542849
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

We have previously demonstrated that lysophosphatidic acid (LPA) production in the spinal cord following partial sciatic nerve injury (SCNI) and its signaling initiate neuropathic pain. In order to examine whether LPA production depends on the intense nociceptive signal, we have attempted to see suppression by pre-emptive treatment with centrally administered morphine, which mainly inhibits nociceptive signal at the level of spinal cord. In the present study, we developed a quantitative mass spectrometry assay to simultaneously analyze several species of lysophosphatidyl choline (LPC). The levels of 16:0-, 18:0- and 18:1-LPC in the spinal cord and dorsal root were maximally increased at 75 min after SCNI and then declined, as LPC is converted to LPA by autotaxin (ATX). In atx(+/-)-mice, on the other hand, these levels were similar to wild-type mice at 75 min, but maximal at 120 min, suggesting that this difference is partly due to the low conversion of LPC to LPA in atx(+/-)-mice. When morphine was centrally administered before SCNI, the injury-induced increase of LPC was completely abolished. These results suggest that LPC (or LPA) is produced by injury-induced nociceptive signal, which is effectively and pre-emptively suppressed by central morphine, possibly through known descending anti-nociceptive pathways.

Citing Articles

Blood metabolomic profile in patients with type 2 diabetes mellitus with diabetic peripheral neuropathic pain.

Kuo H, Lin C, Tsai S, Chen C, Lyu R, Chu C J Diabetes Investig. 2024; 16(2):246-256.

PMID: 39548809 PMC: 11786186. DOI: 10.1111/jdi.14355.


Randomised, double-blind, placebo-controlled, parallel-group, multicentric, phase IIA clinical trial for evaluating the safety, tolerability, and therapeutic efficacy of daily oral administration of NFX88 to treat neuropathic pain in individuals....

Escriba P, Gil-Agudo A, Vidal Samso J, Sanchez-Raya J, Salvador-de la Barrera S, Soto-Leon V Spinal Cord. 2024; 62(8):454-467.

PMID: 38898145 PMC: 11300303. DOI: 10.1038/s41393-024-01006-4.


Lysophosphatidylcholine: Potential Target for the Treatment of Chronic Pain.

Ren J, Lin J, Yu L, Yan M Int J Mol Sci. 2022; 23(15).

PMID: 35955410 PMC: 9368269. DOI: 10.3390/ijms23158274.


Lysophosphatidic Acid Signalling in Nervous System Development and Function.

Birgbauer E Neuromolecular Med. 2020; 23(1):68-85.

PMID: 33151452 PMC: 11420905. DOI: 10.1007/s12017-020-08630-2.


Alteration of the lysophosphatidic acid and its precursor lysophosphatidylcholine levels in spinal cord stenosis: A study using a rat cauda equina compression model.

Uranbileg B, Ito N, Kurano M, Saigusa D, Saito R, Uruno A Sci Rep. 2019; 9(1):16578.

PMID: 31719574 PMC: 6851136. DOI: 10.1038/s41598-019-52999-5.